Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · Real-Time Price · USD
38.22
-0.01 (-0.03%)
At close: Mar 9, 2026, 4:00 PM EDT
38.20
-0.02 (-0.05%)
After-hours: Mar 9, 2026, 6:16 PM EDT

Crinetics Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Net Income
-465.32-298.41-214.53-163.92-107.64
Upgrade
Depreciation & Amortization
3.892.791.10.980.92
Upgrade
Loss (Gain) From Sale of Assets
0.050.050.01--
Upgrade
Loss (Gain) From Sale of Investments
-15.43-14.93-6.270.030.42
Upgrade
Loss (Gain) on Equity Investments
-0.475.21.01-
Upgrade
Stock-Based Compensation
91.0269.3940.9428.2717.35
Upgrade
Other Operating Activities
3.013.04-0.79-0.19-0.74
Upgrade
Change in Accounts Receivable
-0.59----
Upgrade
Change in Inventory
-2.02----
Upgrade
Change in Accounts Payable
28.9813.3212.3610.996.29
Upgrade
Change in Unearned Revenue
-1.840.07-1.548.34-
Upgrade
Change in Other Net Operating Assets
-19.69-5.98-5.07-0.72-5.2
Upgrade
Operating Cash Flow
-377.92-230.19-168.6-115.21-88.59
Upgrade
Capital Expenditures
-5.76-3.84-4.69-1.66-0.44
Upgrade
Investment in Securities
179.67-570.97-195.73-172.32-56.05
Upgrade
Investing Cash Flow
173.91-574.82-200.41-173.98-56.48
Upgrade
Issuance of Common Stock
40.611,030391.78129.72265.64
Upgrade
Other Financing Activities
--14.98-0.54-7.76-12.96
Upgrade
Financing Cash Flow
40.611,015391.24121.96252.68
Upgrade
Foreign Exchange Rate Adjustments
-0.11----
Upgrade
Net Cash Flow
-163.51209.6522.22-167.22107.61
Upgrade
Free Cash Flow
-383.68-234.04-173.29-116.86-89.02
Upgrade
Free Cash Flow Margin
-4985.50%-22525.31%-4318.12%-2466.98%-8258.26%
Upgrade
Free Cash Flow Per Share
-4.08-2.90-2.98-2.25-2.32
Upgrade
Levered Free Cash Flow
-206.91-136.41-93.53-62.51-48.47
Upgrade
Unlevered Free Cash Flow
-206.91-136.41-93.53-62.51-48.47
Upgrade
Change in Working Capital
4.847.415.7518.611.1
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.